THERAPY DOSSIER · th-c6f4fff27e9e

Isorhapontigenin and heyneanol-A (resveratrol analogues), with resveratrol as comparator

Nutraceutical

Evidence & regulatory context

Mechanism: Not recorded
Target: Not recorded
Injury models: Radiation
Reported indication: Not recorded
First approval: Not recorded
Development stage: Not recorded
ChEMBL record: Not recorded
ChEMBL max phase: Not recorded
Synonyms: Not recorded
Note: Not recorded

Clinical trials 0

0 linked trials carry an injury-indication flag. These flags support record-level exploration and sit alongside the stringent aggregate counts described in Methods.

No linked human trial in this dataset.

Preclinical evidence 1

1 studies reported at therapy level; 1 evidence entries itemised.

PMID 25050334 ↗2014Reported benefit

Administration of the resveratrol analogues isorhapontigenin and heyneanol-A protects mice hematopoietic cells against irradiation injuries.

MouseRadiationC57BL/6 (donor C57BL/6-Ly-5.1, recipient C57BL/6-Ly-5.2)Malen = Seven recipient mice per group in competitive repopulation…In vitro incubation of bone marrow mononuclear cells0.01 to 100 micromolar for viability assays; 0.01 to 1 micr…Incubation for 60 minutes before irradiation

Model: Ex vivo gamma irradiation of bone marrow mononuclear cells at 1, 2 or 4 Gy at 0.76 Gy/min; recipients received 9.0 Gy total body irradiation before transplantation

Heyneanol-A, isorhapontigenin and resveratrol improved viability of irradiated bone marrow mononuclear cells and CFU-GM colony formation. Heyneanol-A and resveratrol also enhanced long-term multilineage engraftment, increasing donor engraftment by 13.07% and 11.58% respectively at 2 months, whereas…

Extraction: extract · Supplied extraction confidence: 0.9. Machine-extracted fields require source verification.

Loading the evidence…